Chongqing Tan

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma

Xiaomin Wan, Yucong Zhang, Chongqing Tan et al. · JAMA Oncology · 2019 · 152 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Xiaomin Wan, Xia Luo, Chongqing Tan et al. · Cancer · 2019 · 107 citations · Full text

Medicine, Oncology, Pharmacoeconomics +16

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Qiao Liu, Zhen Zhou, Xiaohui Zeng et al. · Frontiers in Pharmacology · 2021 · 53 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer

Chongqing Tan, Xiaohui Zeng, Jianhe Li et al. · PharmacoEconomics · 2013 · 51 citations

Medicine, Oncology, Surgery +17

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

Siying Wang, Liubao Peng, Jianhe Li et al. · PLoS ONE · 2013 · 51 citations · Full text

Medicine, Oncology, Pharmacoeconomics +13